ViiV Healthcare announces phase III GEMINI studies of dolutegravir and lamivudine meets primary endpoint

10:55 EDT 15 Jun 2018 | PharmaBiz

ViiV Healthcare has announced positive headline results from its phase III GEMINI study programme.

More From BioPortfolio on "ViiV Healthcare announces phase III GEMINI studies of dolutegravir and lamivudine meets primary endpoint"